Nusinersen: Single-Centre Real-Life Experience in Type 1 Spinal Muscular Atrophy
Introduction: Nusinersen, an antisense oligonucleotide designed to treat spinal muscular atrophy, led to substantial motor milestone achievements in clinical trials. The aim of this study was to report the clinical outcome of children diagnosed with spinal muscular atrophy type 1 treated with nusin...
Enregistré dans:
| Auteurs principaux: | , , , , , , , |
|---|---|
| Format: | article |
| Langue: | EN PT |
| Publié: |
Sociedade Portuguesa de Pediatria
2021
|
| Sujets: | |
| Accès en ligne: | https://doaj.org/article/828fb533814c45c68d07e54b9f60eae3 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|